Risdiplam in Patients Previously Treated with Other Therapies for Spinal Muscular Atrophy: An Interim Analysis from the JEWELFISH Study

被引：0
|
作者：
Claudia A. Chiriboga
Claudio Bruno
Tina Duong
Dirk Fischer
Eugenio Mercuri
Janbernd Kirschner
Anna Kostera-Pruszczyk
Birgit Jaber
Ksenija Gorni
Heidemarie Kletzl
Imogen Carruthers
Carmen Martin
Francis Warren
Renata S. Scalco
Kathryn R. Wagner
Francesco Muntoni
机构：
[1] Columbia University Irving Medical Center,Department of Neurology
[2] University of Genoa,Centre of Translational and Experimental Myology, IRCCS Istituto Giannina Gaslini, and Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health
[3] Stanford University,DINOGMI
[4] University Children’s Hospital Basel,Department of Neurology
[5] University of Basel,Division of Neuropediatrics
[6] Fondazione Policlinico Gemelli IRCCS,Pediatric Neurology Institute, Catholic University and Nemo Pediatrico
[7] Medical Center-University of Freiburg,Department of Neuropediatrics and Muscle Disorders, Faculty of Medicine
[8] Medical University of Warsaw,Department of Neurology
[9] ERN EURO-NMD,Roche Pharmaceutical Research and Early Development
[10] Pharma Development,Product Development Neuroscience
[11] Safety,The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre
[12] F. Hoffmann-La Roche Ltd,undefined
[13] PDMA Neuroscience and Rare Disease,undefined
[14] F. Hoffmann-La Roche Ltd,undefined
[15] Roche Innovation Center Basel,undefined
[16] Roche Products Ltd,undefined
[17] F. Hoffmann-La Roche Ltd,undefined
[18] Great Ormond Street Institute of Child Health University College London,undefined
[19] and Great Ormond Street Hospital Trust,undefined
来源：
Neurology and Therapy | 2023年 / 12卷
关键词：
Evrysdi; Pharmacodynamics; Risdiplam; Safety; Spinal muscular atrophy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：543 / 557
页数：14
相关论文
共 50 条
  • [21] A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam
    Schon, Miguel
    Domingues, Sara
    Moreno, Teresa
    Santos, Miguel Oliveira
    NEUROLOGICAL SCIENCES, 2023, 44 (04) : 1449 - 1450
  • [22] A severely affected adult type 2 spinal muscular atrophy patient treated with risdiplam
    Miguel Schön
    Sara Domingues
    Teresa Moreno
    Miguel Oliveira Santos
    Neurological Sciences, 2023, 44 : 1449 - 1450
  • [23] Risdiplam treatment has not led to retinal toxicity in patients with spinal muscular atrophy
    Sergott, Robert C.
    Amorelli, Giulia M.
    Baranello, Giovanni
    Barreau, Emmanuel
    Beres, Shannon
    Kane, Steven
    Mercuri, Eugenio
    Orazi, Lorenzo
    SantaMaria, Melissa
    Tremolada, Gemma
    Santarsiero, Diletta
    Waskowska, Agnieszka
    Yashiro, Shigeko
    Denk, Nora
    Furst-Recktenwald, Sabine
    Gerber, Marianne
    Gorni, Ksenija
    Jaber, Birgit
    Jacobsen, Bjoern
    Mueller, Lutz
    Nave, Stephane
    Scalco, Renata S.
    Marzoli, Stefania B.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2021, 8 (01): : 54 - 65
  • [24] Fertility outcomes in risdiplam-treated male patients with spinal muscular atrophy (SMA): a multicenter case series
    Erdler, M.
    Coskery, S.
    Frey, M.
    Lopez, M.
    NEUROMUSCULAR DISORDERS, 2024, 43
  • [25] Efficacy of risdiplam in spinal muscular atrophy: A systematic review and meta-analysis
    Pascual-Morena, Carlos
    Martinez-Vizcaino, Vicente
    Cavero-Redondo, Ivan
    Martinez-Garcia, Irene
    Moreno-Herraiz, Nerea
    Alvarez-Bueno, Celia
    Saz-Lara, Alicia
    PHARMACOTHERAPY, 2024, 44 (01): : 97 - 105
  • [26] Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls
    Darras, Basil T.
    Masson, Riccardo
    Mazurkiewicz-Beldzinska, Maria
    Rose, Kristy
    Xiong, Hui
    Zanoteli, Edmar
    Baranello, Giovanni
    Bruno, Claudio
    Vlodavets, Dmitry
    Wang, Yi
    El-Khairi, Muna
    Gerber, Marianne
    Gorni, Ksenija
    Khwaja, Omar
    Kletzl, Heidemarie
    Scalco, Renata S.
    Fontoura, Paulo
    Servais, Laurent
    NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (05): : 427 - 435
  • [27] An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies
    Giess, Doris
    Erdos, Judit
    Wild, Claudia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2024, 51 : 84 - 92
  • [28] Switching from Nusinersen to Risdiplam in Spinal Muscular Atrophy: A Comparative Analysis of Safety, Efficacy, and Economic Impact
    Castellana, Eleonora
    HOSPITAL PHARMACY, 2025, 60 (02) : 103 - 104
  • [29] RISDIPLAM THROUGH THE UK EARLY ACCESS TO MEDICINES SCHEME FOR PATIENTS WITH SPINAL MUSCULAR ATROPHY
    Scoto, Mariacristina
    Galtrey, Clare
    Hewamadduma, Channa
    Keane, Paul
    Lilleker, James B.
    Marini-Bettolo, Chiara
    Phillips, Zoe
    Sharp, Becky
    Wenham, Andrew
    Baranello, Giovanni
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09):
  • [30] An expanded access program of risdiplam for patients with Type 1 or 2 spinal muscular atrophy
    Kwon, Jennifer M.
    Arya, Kapil
    Kuntz, Nancy
    Phan, Han C.
    Sieburg, Cory
    Swoboda, Kathryn J.
    Veerapandiyan, Aravindhan
    Assman, Beverly
    Bader-Weder, Silvia
    Dickendesher, Travis L.
    Hansen, Jennifer
    Lin, Helen
    Yan, Ying
    Rao, Vamshi K.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2022, 9 (06): : 810 - 818
12345